EPISODE 049
Lisa Wipperman Heine, COO of Mitralign, says the FDA is making quicker work of review times. But the same might not be said for other countries where Medtechs once had a faster time to market. In this interview at the offices of Fox Rothschild in Minneapolis, the Medtech veteran lays out Mitralign’s success with the agency’s Early Feasibility program.
Read more about Mitralign here.
Podcast Guest
Lisa Wipperman Heine
COO
Mitralign
Lisa Wipperman Heine is currently Chief Operating Officer at Mitralign, Inc., a venture-backed innovator of transcatheter heart valve technologies. Prior to joining Mitralign, she was the Founder and Principal at deArca Strategic Solutions, LLC, a consulting firm focused on helping medtech companies assess, develop and execute strategies related to market opportunities and technology adoption. Lisa has also served in multiple leadership roles at Covidien, Inc., including Global Vice President of Medical Affairs for Vascular Therapies. During her tenure at Covidien, she helped drive the strategy in support of a $1.7B business and was also responsible for leading the strategy and operations of Clinical Affairs, Healthcare Economics, Policy and Reimbursement and Medical Education functions. Lisa also currently serves as a member of the Board of Directors of Surmodics Inc. (NASDAQ: SRDX).
She received her BA from St. Olaf College and MSC from the University of Manitoba.
Meet Our Host
Geoff Pardo
Geoff has been in medtech for over two decades in both operational and investment roles. He is passionate about the industry potential and sharing stories from the front lines of innovation.